Showing results (131-140 of 297) with videos related to
Sort By:
Pageof 30
Breast Cancer Research and Treatment|October 16, 2015
Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?John Semple, Kelly A Metcalfe, Jan Lubinski, et al.Wiener Medizinische Wochenschrift (1946)|October 17, 2015
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statementEdgar Petru, Christian F Singer, Stephan Polterauer, et al.Molecular Oncology|June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progressionEva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.BMC Cancer|November 8, 2018
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.Oncotarget|January 14, 2017
Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cellsRenate Wagner, Gerald Stübiger, Daniel Veigel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trialGeorg Pfeiler, Robert Königsberg, Christian Fesl, et al.British Journal of Cancer|March 2, 2025
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancerAriane Steindl, Clara Zach, Luzia Berchtold, et al.Journal of Experimental & Clinical Cancer Research : CR|November 14, 2023
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patientsKerstin Wimmer, Monika Sachet, Cristiano Ramos, et al.European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter C Dubsky, Christian F Singer, Daniel Egle, et al.Breast Cancer Research and Treatment|January 19, 2016
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control studyJoanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, et al.Pageof 30